| Nov 14 |
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum
|
| Nov 13 |
Entero mulls reverse merger with Journey Therapeutics
|
| Nov 13 |
Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
|
| Sep 16 |
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
|
| Sep 10 |
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
|
| Aug 23 |
Entero Therapeutics receives Nasdaq notification regarding delayed form 10-Q
|
| Aug 23 |
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
|
| Jul 31 |
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
|
| Jul 26 |
Entero Therapeutics files secondary offering of 3.5M shares
|
| Jul 11 |
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
|
